Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Ethacridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | CASP7 | P55210 | 3/20 | 0.98 |
| ▸ | CASP1 | P29466 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 2/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | TERT | O14746 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethacridine SCHEMBL29568982 | 1.00 | MEN1 (0.98) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL1649444 | 1.00 | MEN1 (0.98) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL8676831 | 1.00 | MEN1 (0.98) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL138154 | 0.99 | MEN1 (1.00) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL31197660 | 0.99 | MEN1 (1.00) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL30006678 | 0.99 | MEN1 (1.00) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL30775016 | 0.99 | MEN1 (1.00) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL3967085 | 0.97 | MEN1 (0.96) | MEN1KMT2ACASP7CASP1KDM4E | |
| Lactic Acid SCHEMBL8375854 | 0.94 | MEN1 (0.91) | MEN1KMT2ACASP7CASP1KDM4E | |
| Ethacridine SCHEMBL30753462 | 0.89 | MEN1 (0.97) | MEN1KMT2ACASP7CASP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151983-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | SCORE PHARMA, INC. | 2022-05-19 | — | — | US | claimed |
| EP-3941480-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | Score Pharma Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| EP-4674476-A1 | MAGNETIC FIELD VARIATION THERAPY FOR ENHANCING THERAPEUTIC AND DISINFECTION APPLICATIONS | Azyro SA (LU) | 2026-01-07 | — | — | EP | disclosed |
| US-20250387303-A1 | Antimicrobial Dental Varnishes Based On Cationic Polymer Dispersions | IVOCLAR VIVADENT AG (LI) | 2025-12-25 | — | — | US | disclosed |
| US-20250387315-A1 | Dental Varnishes Based On Cationic Polymer Dispersions | IVOCLAR VIVADENT AG (LI) | 2025-12-25 | — | — | US | disclosed |
| CN-118109495-A | Application of phosphokinase KinA in improving yield of bacillus active secondary metabolite | 华南农业大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-112955009-B | Composition, sprayer and wiping cloth | 富士胶片株式会社 | 2022-10-25 | — | — | CN | disclosed |
| US-20220151983-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | SCORE PHARMA, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3941480-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | Score Pharma Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387315-A1 | Dental Varnishes Based On Cationic Polymer Dispersions | TUBA3C, DNMT1, TUBA1A | MEN1 1275/4885KMT2A 995/4885CASP7 129/4885 |
| US-20220151983-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | FUCA2, FUCA1, FUT5 | MEN1 2031/4885KMT2A 2142/4885CASP7 4054/4885 |
| US-20250387303-A1 | Antimicrobial Dental Varnishes Based On Cationic Polymer Dispersions | TAS2R10, TAS2R40, TAS2R41 | MEN1 4011/4885KMT2A 2540/4885CASP7 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.